Prolactinoma is the most common hormone-secreting pituitary adenoma. The approach to prolactinomas has changed in the past 25 years, thanks to treatment with dopamine agonists, which is characterized by a potent prolactin inhibitory effect, a tumor-shrinking effect, and a good tolerability. Cabergoline is a new dopamine agonist with a natural long duration of action and selectivity for the D2 receptor. The authors discuss the criteria for stopping treatment with cabergoline in prolactinomas. According to their experience, they withdraw cabergoline treatment in prolactinomas after normalization of serum prolactin levels and tumor disappearance or no further reduction of tumor size on MRI during the last 12 months of follow-up.
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism